Clinical Trial Search

Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…

Primary: Change in CD8+ T-cell Activation From Baseline to Week 14/16 — 3.24; 0.52 percentage of cells — p=0.030

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Number of Grade 2 or Greater AEs — 10; 2 Participants — p=0.07

Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…

Primary: Symptom Score — 10; 8 units on a scale — p=0.45

Primary: Number of Serious Adverse Events (SAEs) — 12; 7 Events

Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70

Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml

Primary: Antibody Titer (Serum Anti-Aβ1-42 Free IgG) - Mean Absolute Value — 632.3; 335.4; 162.8; 751.5 AU/mL (AU: Arbitrary Unit)

Primary: New or Recurrent Disease Progression Events, as Defined, or Death. — 110; 119 Participants — p=0.47

Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94